Connect with us
[bsa_pro_ad_space id=12]

COVID-19

We all want this crisis to end. Read this. Then find a mask and put it on when you go out in public

Published

14 minute read

This is article is abridged for your convenience.

Public use of masks to control the coronavirus pandemic

(Originally published March 29 by Longrich Paleo Lab)

Nicholas R. Longrich, PhD

Department of Biology and Biochemistry, University of Bath, Bath, United Kingdom

The Longrich Paleontology Lab is part of the Milner Centre for Evolution at the University of Bath. We use fossils to understand large-scale evolutionary change in organisms and ecosystems. 

The US and UK governments, as well as the World Health Organization, currently advise against the use of masks by the public to fight the ongoing Coronavirus Disease 19 (COVID-19) pandemic (1). But could they be wrong?

The governments of China, South Korea, Hong Kong, Viet Nam, Czechia, Slovakia, Bosnia and Taiwan all recommend that the public wear masks to slow the spread of the coronavirus. In some countries, like Japan, masks aren’t officially recommended, but are still widely used by the public. Many countries treat masks as a strategic resource. China has ramped up production of facemasks, converting Foxconn factories that once made iPhones to make face masks. Taiwan has also ramped up the production of facemasks, prohibited their export, and implemented price controls and rationing. It’s hard to see how both approaches could be right. Increasingly, advice against the use of face masks has been questioned (1) (2) (3), including by the head of China’s CDC (4). Austria has recently moved to make mask wearing in public obligatory, and in the United States, the CDC is now debating their use.

Common sense, scientific studies, but perhaps most of all the success of countries using masks to fight the coronavirus suggest that masks may make a difference. There are fewer scientific studies available to guide decision making than we might like, and the evidence is not always clear-cut. However, decision-making in a crisis requires that decisions be made in the absence of perfect clarity. What is clear is that the exponential mathematics of pandemics mean that even if masks are of limited benefit in reducing infection rates, masks could make a large difference over time, potentially slowing the pace of the pandemic, limiting its spread, saving lives, and finally, letting countries to restart the economies that their people depend on for their livelihoods.

Figure produced by Johns Hopkins University using data from Worldometers on March 29.

Masks protect you from others, others from you

It seems sensible to assume that any barrier between two people’s airways reduces the chance of an air-borne virus being transmitted between them. Masks worn by infected people catch some fraction of virus-laden respiratory droplets that are released by breathing and coughing. Perhaps just as important, breathing through a mask slows and deflects air as it is exhaled, potentially reducing the distance that viral droplets travel as aerosols.

Meanwhile, masks worn by uninfected people catch a fraction of the virus they’d otherwise inhale. If both infected and uninfected people wear masks, then these effects multiply. For example, hypothetically, if an infected person’s mask reduces the amount of virus spread by 75%, and the uninfected person’s mask reduces it by another 75%, then the total reduction of the virus spread is 94%.

It’s still possible that this reduction isn’t enough to prevent infection. However, masks could still protect people— because dosage matters. Lower dosing of virus means infection takes longer to build up, giving the immune system time to mount a response.

The immune system fights viruses, like a farmer trying to remove weeds from his field. How difficult those weeds will be to control depends on how many seeds there are. 1000 seeds in a field might not be a challenge, but 1,000,000 or 100 million make weeding far more difficult. In the same way, even when masks fail to prevent infection, by lowering the initial dose of virus they could  conceivably make the difference between mild symptoms and a severe illness requiring hospitalization, or even leading to death.

Models suggest masks could work to control pandemics

Of course, it’s possible that masks might have only limited benefit in stopping the spread of COVID-19— for any number of reasons.  Masks might provide limited protection, because they are less effective than suggested by some studies, because people misuse them, because of shortages of effective masks like surgical masks and N-95s— or all of these.

But to understand how they could still make a difference, we have to consider masks in the context of small reductions in viral transmission rates. Consider how epidemics grow— exponentially. Allowed to spread unchecked, one case of Covid-19 becomes 2.5 (assuming for this model an R0 of 2.5), each case causing 2.5 more, and so on. Over the course of 15 reproductive cycles, each taking 7 days, or about 3 months in total, one case becomes 2.5 x 2.5 x 25… or 2.5^15 =   931,323 cases (Fig. 1).

1 Figure 1 Small Reductions in R.png

Figure 1. A simple model showing exponential growth in an uncontained outbreak over time (generation time = 7 days, R0 = 2.5) and with small reductions in the reproductive rate R.

Now, let’s suppose widespread use of masks cuts the growth rate by just 10%. Each person now infects 2.25 others, who infect 2.25 others, and so on. Over 15 cycles, 2.25^15 = 191,751 cases. An 80% reduction. Understanding this exponential growth explains how the virus caught the world by surprise even as the pandemic was monitored in real time. Exponential growth just doesn’t make sense, until you do the numbers, and even, they’re still hard to believe. But another counterintuitive aspect of exponential growth is that small decreases in the exponent greatly slow growth. A 10% increase in the exponent can have a massive effect, but even a limited intervention, with a 10% decrease over time, pays large dividends (Fig. 1).

These are very, very simple models. But sophisticated modeling also shows large scale use of masks could slow, even stop pandemics. A 2010 study found that above a certain threshold, widespread use of effective masks can reduce the reproductive number (R) of an influenza virus below 1, and the pandemic stops (25). If face masks were highly effective (well-designed, used properly and consistently), then public use of masks could stop a flu pandemic if used by just 50% of people. If masks were less effective, more than half the population would have to wear them to stop the pandemic. If masks were highly ineffective, they could flatten the curve of the epidemic, but wouldn’t stop it (25). We don’t know which model is most accurate. But does it even matter? In the context of the current pandemic, any of these scenarios would be a huge win.

Real world experience suggests masks work in pandemics

The most compelling evidence of the potential effectiveness of masks in the fight against COVID-19 comes from their use in the real world. Places that have controlled their coronavirus epidemics most effectively – China, South Korea, Hong Kong, Taiwan, Vietnam, Singapore, Kuwait, Czechia, Slovakia, Japan- use masks (Fig. 2). Aside from China, which was the epicenter of the pandemic and so played catchup in developing and implementing its strategy, virtually all of the worst outbreaks are in Western countries that officially advise against mask use, and where there is little culture or practice of mask wearing.

2 Figure 2 31st.png

Figure 2. Western countries (US, Canada, Australia, UK, Western Europe) versus countries and territories using masks as part of official government or in practice policy (China, South Korea, Japan, Hong Kong, Taiwan, Vietnam, Thailand, Kuwait, Slovakia, Czech Republic, in blues and greens). Countries with official or unofficial policies of mask usage have controlled the outbreak far better than those without. Note that Austria currently uses masks but has only revised its official policy recently.

Places like China, South Korea, Taiwan, Vietnam, Kuwait, Czechia and Singapore differ greatly in political organization, ranging from communism to democracies, and also in their level of economic development and population density. And strikingly, these countries also differ in their suppression strategies. China implemented a lockdown of Wuhan, shut down industry nationwide, implemented temperature checks and social distancing, tested extensively— and employed masks. Korea responded with an aggressive testing and contact tracing—and masks. Japan has done far less extensive testing than Korea, but shut down schools and large gatherings— and used masks. The pandemic management strategies used by these countries far more diverse than has been appreciated. Arguably one of the few things all these successes share is widespread wearing of masks. And on the other hand, one common factor shared by the pandemic suppression strategies of the US, Canada, the UK and Europe is the decision to discourage the use of masks by the public. This evidence doesn’t prove, but it does very strongly hint that masks are a critical part of these country’s suppression strategies. And by watching countries like Austria that have recently revised their policies, we can test this idea.

What kind of mask? Surgical masks as good as N95s; are improvised masks better than nothing?

Would cloth masks work? Research into the effectiveness of cloth masks is limited  (34). Existing research shows homemade masks are- unsurprisingly- inferior to surgical masks. However, they appear to be better than nothing. One laboratory study found homemade masks were half as effective as surgical masks in filtering particles (35). Another study found homemade masks made from various materials stopped virus aerosols, but less well than surgical masks (36). A surgical mask stopped 90% of viral aerosol particles, a dish towel, 72%, linen, 62%, and a cotton T-shirt, 51% (36).

Conclusions

Strong scientific evidence and rational arguments exist for the widespread, public use of facemasks. The principle behind facemasks- they reduce the amount of virus exhaled by infected people, and inhaled by uninfected- suggest they should be a primary tool in combating any respiratory virus. Scientific research, including experimental studies, retrospective studies of the SARS epidemic, hospital studies of COVID-19, and modeling studies, all suggests masks are likely to be effective in controlling the pandemic. Most importantly, the experience of countries using masks against SARS and the current coronavirus pandemic imply that they are effective when used by the public. However, modeling studies and the real-world experience of countries like China and South Korea suggests that neither masks, nor anything else, provides a magic bullet against a pandemic. So strategies should not rely on any single intervention, but rather a wide range of interventions, potentially including masks. Further research and open debate on the effectiveness of masks and other strategies are urgently needed.

Flames GM Brad Treliving does what he can to be ready for NHL reboot

 

After 15 years as a TV reporter with Global and CBC and as news director of RDTV in Red Deer, Duane set out on his own 2008 as a visual storyteller. During this period, he became fascinated with a burgeoning online world and how it could better serve local communities. This fascination led to Todayville, launched in 2016.

Follow Author

COVID-19

Study finds Pfizer COVID vaccine poses 37% greater mortality risk than Moderna

Published on

From LifeSiteNews

By Nicolas Hulscher, MPH

A study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause mortality after Pfizer vaccination compared to Moderna

A new study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause, cardiovascular, and COVID-19 mortality after Pfizer vaccination.

The study titled “Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or mRNA-1273 among Adults Living in Florida” was just uploaded to the MedRxiv preprint server. This study was headed by MIT Professor Retsef Levi, with Florida Surgeon General Dr. Joseph Ladapo serving as senior author:

Study Overview

  • Population: 1,470,100 noninstitutionalized Florida adults (735,050 Pfizer recipients and 735,050 Moderna recipients).
  • Intervention: Two doses of either:
    • BNT162b2 (Pfizer-BioNTech)
    • mRNA-1273 (Moderna)
  • Follow-up Duration: 12 months after second dose.
  • Comparison: Head-to-head between Pfizer vs. Moderna recipients.
  • Main Outcomes:
    • All-cause mortality
    • Cardiovascular mortality
    • COVID-19 mortality
    • Non-COVID-19 mortality

All-cause mortality

Pfizer recipients had a significantly higher 12-month all-cause death rate than Moderna recipients — about 37% higher risk.

  • Pfizer Risk: 847.2 deaths per 100,000 people
  • Moderna Risk: 617.9 deaths per 100,000 people
  • Risk Difference:
    ➔ +229.2 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.37 (i.e., 37% higher mortality risk with Pfizer)
  • Odds Ratio (Adjusted):
    ➔ 1.384 (95% CI: 1.331–1.439)

Cardiovascular mortality

Pfizer recipients had a 53% higher risk of dying from cardiovascular causes compared to Moderna recipients.

  • Pfizer Risk: 248.7 deaths per 100,000 people
  • Moderna Risk: 162.4 deaths per 100,000 people
  • Risk Difference:
    ➔ +86.3 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.53 (i.e., 53% higher cardiovascular mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.540 (95% CI: 1.431–1.657)

COVID-19 mortality

Pfizer recipients had nearly double the risk of COVID-19 death compared to Moderna recipients.

  • Pfizer Risk: 55.5 deaths per 100,000 people
  • Moderna Risk: 29.5 deaths per 100,000 people
  • Risk Difference:
    ➔ +26.0 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.88 (i.e., 88% higher COVID-19 mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.882 (95% CI: 1.596–2.220)

Non-COVID-19 mortality

Pfizer recipients faced a 35% higher risk of dying from non-COVID causes compared to Moderna recipients.

  • Pfizer Risk: 791.6 deaths per 100,000 people
  • Moderna Risk: 588.4 deaths per 100,000 people
  • Risk Difference:
    ➔ +203.3 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.35 (i.e., 35% higher non-COVID mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.356 (95% CI: 1.303–1.412)

Biological explanations

The findings of this study are surprising, given that Moderna’s mRNA-1273 vaccine contains approximately three times more mRNA (100 µg) than Pfizer’s BNT162b2 vaccine (30 µg). This suggests that the higher mortality observed among Pfizer recipients could potentially be related to higher levels of DNA contamination — an issue that has been consistently reported worldwide:

The paper hypothesizes differences between Pfizer and Moderna may be due to:

  • Different lipid nanoparticle compositions
  • Differences in manufacturing, biodistribution, or storage conditions

Final conclusion

Florida adults who received Pfizer’s BNT162b2 vaccine had higher 12-month risks of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality compared to Moderna’s mRNA-1273 vaccine recipients.

Unfortunately, without an unvaccinated group, the study cannot determine the absolute increase in mortality risk attributable to mRNA vaccination itself. However, based on the mountain of existing evidence, it is likely that an unvaccinated cohort would have experienced much lower mortality risks. It’s also important to remember that Moderna mRNA injections are still dangerous.

As the authors conclude:

These findings are suggestive of differential non-specific effects of the BNT162b2 and mRNA-1273 COVID-19 vaccines, and potential concerning adverse effects on all-cause and cardiovascular mortality. They underscore the need to evaluate vaccines using clinical endpoints that extend beyond their targeted diseases.

Nicolas Hulscher, MPH

Epidemiologist and Foundation Administrator, McCullough Foundation

www.mcculloughfnd.org

Please consider following both the McCullough Foundation and my personal accounton X (formerly Twitter) for further content.

Reprinted with permission from Focal Points.

Continue Reading

COVID-19

Canada’s health department warns COVID vaccine injury payouts to exceed $75 million budget

Published on

Fr0m LifeSiteNews

By Clare Marie Merkowsky

A Department of Health memo warns that Canada’s Vaccine Injury Support Program will exceed its $75 million budget due to high demand, with $16 million already paid out.

COVID vaccine injury payments are expected to go over budget, according to a Canadian Department of Health memo.

According to information published April 28 by Blacklock’s Reporter, the Department of Health will exceed their projected payouts for COVID vaccine injuries, despite already spending $16 million on compensating those harmed by the once-mandated experimental shots.

“A total $75 million in funding has been earmarked for the first five years of the program and $9 million on an ongoing basis,” the December memo read. “However the overall cost of the program is dependent on the volume of claims and compensation awarded over time, and that the demand remains at very high levels.”

“The purpose of this funding is to ensure people in Canada who experience a serious and permanent injury as a result of receiving a Health Canada authorized vaccine administered in Canada on or after December 8, 2020 have access to a fair and timely financial support mechanism,” it continued.

Canada’s Vaccine Injury Support Program (VISP) was launched in December 2020 after the Canadian government gave vaccine makers a shield from liability regarding COVID-19 jab-related injuries.

While Parliament originally budgeted $75 million, thousands of Canadians have filed claims after received the so-called “safe and effective” COVID shots. Of the 3,060 claims received to date, only 219 had been approved so far, with payouts totaling over $16 million.

Since the start of the COVID crisis, official data shows that the virus has been listed as the cause of death for less than 20 kids in Canada under age 15. This is out of six million children in the age group.

The COVID jabs approved in Canada have also been associated with severe side effects such as blood clots, rashes, miscarriages, and even heart attacks in young, healthy men.

Additionally, a recent study done by researchers with Canada-based Correlation Research in the Public Interest showed that 17 countries have found a “definite causal link” between peaks in all-cause mortality and the fast rollouts of the COVID shots as well as boosters.

Interestingly, while the Department of Health has spent $16 million on injury payouts, the Liberal government spent $54 million COVID propaganda promoting the vaccine to young Canadians.

The Public Health Agency of Canada especially targeted young Canadians ages 18-24 because they “may play down the seriousness of the situation.”

The campaign took place despite the fact that the Liberal government knew about COVID vaccine injuries, according to a secret memo.

Continue Reading

Trending

X